U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
U.S. Warns Allies Over Alleged Chinese AI IP Theft Linked to DeepSeek 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
REDWOOD CITY, Calif., Feb. 18, 2016 -- Avinger, Inc., (NASDAQ:AVGR) a developer and manufacturer of image-guided, catheter-based systems for the treatment of peripheral arterial disease (PAD) and pioneer of the Lumivascular approach to treating vascular disease, today announced that it will release its financial results for the fourth quarter and year-end 2015 after the close of trading on Tuesday, March 1, 2016. The Company will host a corresponding conference call beginning at 1:30pm PT/4:30pm ET.
Individuals interested in listening to the conference call may do so by dialing (855) 638-4817 for domestic callers or (262) 912-6051 for international callers and referencing Conference ID: 38718399. To listen to a live webcast, please visit the investor relations section of Avinger's website at: www.avinger.com.
A replay of the call will be available beginning March 1, 2016 at 4:30pm PT/7:30pm ET through midnight on March 2, 2016. To access the replay, dial (855) 859-2056 or (404) 537-3406 and reference Conference ID: 38718399. The webcast will also be available on Avinger's website for one year following the completion of the call.
About Avinger, Inc.
Avinger, Inc. is a commercial-stage medical device company that designs, manufactures and sells image-guided, catheter-based systems for the treatment of patients with peripheral arterial disease (PAD). PAD is characterized by a build-up of plaque in the arteries that supply blood to the arms and legs. The Company’s mission is to dramatically improve the treatment of vascular disease through the introduction of products based on its lumivascular platform, the only intravascular image-guided system of therapeutic catheters available in this market. Avinger’s current lumivascular products include the Lightbox™ imaging console, the Ocelot™ family of catheters, which are designed to penetrate total arterial blockages, known as chronic total occlusions, or CTOs, and Pantheris™, the first-ever image-guided atherectomy device, designed to precisely remove arterial plaque in PAD patients. For more information, please visit the Company's website at www.avinger.com.
"Avinger," “Pantheris” and the Avinger logo are registered trademarks of Avinger, Inc.
Investor Contact: Westwicke Partners Leigh Salvo (415) 513-1281 Email: [email protected]
